Maze Therapeutics press release ( MAZE ): Q4 GAAP EPS of -$0.65 beats by $0.07 . Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028. More on Maze Therapeutics Maze Therapeutics: An Innovative, Nature-Driven Platform Seeking Alpha’s Quant Rating on Maze Therapeutics Historical earnings data for Maze Therapeutics Financial inf...
Maze Therapeutics press release ( MAZE ): Q4 GAAP EPS of -$0.65 beats by $0.07 . Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028. More on Maze Therapeutics Maze Therapeutics: An Innovative, Nature-Driven Platform Seeking Alpha’s Quant Rating on Maze Therapeutics Historical earnings data for Maze Therapeutics Financial information for Maze Therapeutics
Cognyte Software press release ( CGNT ): Q4 Non-GAAP EPS of $0.10 beats by $0.06 . Revenue of $106.24M (+12.4% Y/Y) in-line. FYE27 Outlook Our outlook for the year ending January 31, 2027 (“FYE27” and “Fiscal 2027”) is as follows: Revenue: $448 million vs. $442.60M consensus , with a range of +/- 3%, which represents approximately 12% year-over-year growth at the midpoint of the range. Adjusted EB...
Cognyte Software press release ( CGNT ): Q4 Non-GAAP EPS of $0.10 beats by $0.06 . Revenue of $106.24M (+12.4% Y/Y) in-line. FYE27 Outlook Our outlook for the year ending January 31, 2027 (“FYE27” and “Fiscal 2027”) is as follows: Revenue: $448 million vs. $442.60M consensus , with a range of +/- 3%, which represents approximately 12% year-over-year growth at the midpoint of the range. Adjusted EBITDA: Approximately $68 million at the midpoint of our revenue range, representing approximately 40% year-over-year growth. Non-GAAP Diluted EPS: $0.47 at the midpoint of our revenue range vs. $0.37 consensus . More on Cognyte Software Cognyte Software Needs Better Results To Prove The AI Disruption Narrative False Cognyte Software set to report Q4 2026 earnings preview. Cognyte authorizes $20 million increase to share repurchase program Seeking Alpha’s Quant Rating on Cognyte Software Historical earnings data for Cognyte Software
The Middleby ( MIDD ) has appointed Brittany Cerwin as chief financial officer, effective immediately. Cerwin succeeds Bryan Mittelman, who has served as CFO since 2019 and will transition to the role of special advisor to the chief executive officer. Cerwin previously served as chief accounting officer. Source: Press Release More on Middleby The Middleby Corporation (MIDD) Q4 2025 Earnings Call T...
The Middleby ( MIDD ) has appointed Brittany Cerwin as chief financial officer, effective immediately. Cerwin succeeds Bryan Mittelman, who has served as CFO since 2019 and will transition to the role of special advisor to the chief executive officer. Cerwin previously served as chief accounting officer. Source: Press Release More on Middleby The Middleby Corporation (MIDD) Q4 2025 Earnings Call Transcript The Middleby Corporation 2025 Q4 - Results - Earnings Call Presentation Middleby Making Smarter Moves, But Weak Industry Demand Is A Significant Overhang Middleby outlines $3.27B–$3.36B 2026 revenue target as portfolio optimization accelerates Middleby Q4 2025 Earnings Preview
Israel's Defense Minister says the military will take control of southern Lebanon up to the Litani River to prevent Hezbollah from transporting weapons and fighters. Lebanon has withdrawn accreditation from the Iranian ambassador, demanding his departure from the country by Sunday. Bloomberg's Dan Williams spoke to Joumanna Bercetche on Horizons Middle East and Africa. (Source: Bloomberg)
Israel's Defense Minister says the military will take control of southern Lebanon up to the Litani River to prevent Hezbollah from transporting weapons and fighters. Lebanon has withdrawn accreditation from the Iranian ambassador, demanding his departure from the country by Sunday. Bloomberg's Dan Williams spoke to Joumanna Bercetche on Horizons Middle East and Africa. (Source: Bloomberg)
KalVista Pharmaceuticals press release ( KALV ): Q4 GAAP EPS of -$2.03 may not be comparable to estimates. Revenue of $49.08M beats by $16.79M . As of December 31, 2025, the Company had cash, cash equivalents and marketable securities of approximately $300.2 million. We anticipate that cash, cash equivalents and marketable securities as of December 31, 2025, along with projected revenues associate...
KalVista Pharmaceuticals press release ( KALV ): Q4 GAAP EPS of -$2.03 may not be comparable to estimates. Revenue of $49.08M beats by $16.79M . As of December 31, 2025, the Company had cash, cash equivalents and marketable securities of approximately $300.2 million. We anticipate that cash, cash equivalents and marketable securities as of December 31, 2025, along with projected revenues associated with the sale of EKTERLY will fund the Company through profitability. More on KalVista Pharmaceuticals KalVista Pharmaceuticals: Has Potential But With Caveats KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion KalVista Pharmaceuticals Q4 2025 Earnings Preview Quant snapshot: AAR, Noah Holdings lead strong buys as Blaize, Fractyl Health lag Seeking Alpha’s Quant Rating on KalVista Pharmaceuticals